Why Novavax Could Be the Biggest Winner From Johnson & Johnson's Vaccine Woes

Why Novavax Could Be the Biggest Winner From Johnson & Johnson's Vaccine Woes
Keith Speights, The Motley Fool
·4 min read

Johnson & Johnson (NYSE: JNJ) announced in February 2020 that it planned to develop a COVID-19 vaccine. Recently, though, it's been nothing but bad news for J&J's vaccine. Here's why Novavax (NASDAQ: NVAX) could be the biggest winner from Johnson & Johnson's vaccine woes.